Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + dexamethasone + daratumumab vs carfilzomib + dexamethasone in relapsed/refractory multiple myeloma
jRCT2080223676Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Carfilzomib + daratumumab + dexamethasone with Carfilzomib + dexamethasone (2 arms). Started Oct 2017; status: completed.
02
Drugs
carfilzomibdaratumumabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080223676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223676.